498 related articles for article (PubMed ID: 33068176)
1. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
[TBL] [Abstract][Full Text] [Related]
2. Integrative bioinformatics analysis reveals miR-494 and its target genes as predictive biomarkers of trastuzumab-resistant breast cancer.
Hermawan A; Putri H
J Egypt Natl Canc Inst; 2020 Apr; 32(1):16. PubMed ID: 32372307
[TBL] [Abstract][Full Text] [Related]
3. tRNA-Derived Fragments as Novel Predictive Biomarkers for Trastuzumab-Resistant Breast Cancer.
Sun C; Yang F; Zhang Y; Chu J; Wang J; Wang Y; Zhang Y; Li J; Li Y; Fan R; Li W; Huang X; Wu H; Fu Z; Jiang Z; Yin Y
Cell Physiol Biochem; 2018; 49(2):419-431. PubMed ID: 30153663
[TBL] [Abstract][Full Text] [Related]
4. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
Di Cosimo S; Appierto V; Pizzamiglio S; Tiberio P; Iorio MV; Hilbers F; de Azambuja E; de la Peña L; Izquierdo M; Huober J; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Daidone MG
Clin Cancer Res; 2019 Jul; 25(13):3887-3895. PubMed ID: 30814109
[TBL] [Abstract][Full Text] [Related]
5. Circulating exosomal microRNAs as prognostic biomarkers for non-small-cell lung cancer.
Liu Q; Yu Z; Yuan S; Xie W; Li C; Hu Z; Xiang Y; Wu N; Wu L; Bai L; Li Y
Oncotarget; 2017 Feb; 8(8):13048-13058. PubMed ID: 28055956
[TBL] [Abstract][Full Text] [Related]
6. A miRNA-based signature predicts development of disease recurrence in HER2 positive breast cancer after adjuvant trastuzumab-based treatment.
Du F; Yuan P; Zhao ZT; Yang Z; Wang T; Zhao JD; Luo Y; Ma F; Wang JY; Fan Y; Cai RG; Zhang P; Li Q; Song YM; Xu BH
Sci Rep; 2016 Sep; 6():33825. PubMed ID: 27650797
[TBL] [Abstract][Full Text] [Related]
7. Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Di Cosimo S; Appierto V; Pizzamiglio S; Silvestri M; Baselga J; Piccart M; Huober J; Izquierdo M; de la Pena L; Hilbers FS; de Azambuja E; Untch M; Pusztai L; Pritchard K; Nuciforo P; Vincent-Salomon A; Symmans F; Apolone G; de Braud FG; Iorio MV; Verderio P; Daidone MG
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32085669
[TBL] [Abstract][Full Text] [Related]
8. Exosome-mediated transfer of lncRNA‑SNHG14 promotes trastuzumab chemoresistance in breast cancer.
Dong H; Wang W; Chen R; Zhang Y; Zou K; Ye M; He X; Zhang F; Han J
Int J Oncol; 2018 Sep; 53(3):1013-1026. PubMed ID: 30015837
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
10. Involvement of the Dysregulation of miR-23b-3p, miR-195-5p, miR-656-5p, and miR-340-5p in Trastuzumab Resistance of HER2-Positive Breast Cancer Cells and System Biology Approach to Predict Their Targets Involved in Resistance.
Rezaei Z; Sebzari A; Kordi-Tamandani DM; Dastjerdi K
DNA Cell Biol; 2019 Feb; 38(2):184-192. PubMed ID: 30702337
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-21 as a predictor and prognostic factor for trastuzumab therapy in human epidermal growth factor receptor 2-positive metastatic breast cancer.
Badr M; Said H; Louka ML; Elghazaly HA; Gaballah A; Atef Abd El Mageed M
J Cell Biochem; 2019 Mar; 120(3):3459-3466. PubMed ID: 30246355
[TBL] [Abstract][Full Text] [Related]
13. Identification of serum exosomal miR-148a as a novel prognostic biomarker for breast cancer.
Li D; Wang J; Ma LJ; Yang HB; Jing JF; Jia MM; Zhang XJ; Guo F; Gao JN
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(13):7303-7309. PubMed ID: 32706068
[TBL] [Abstract][Full Text] [Related]
14. Identification of a 7-microRNA signature in plasma as promising biomarker for nasopharyngeal carcinoma detection.
Zhang H; Zou X; Wu L; Zhang S; Wang T; Liu P; Zhu W; Zhu J
Cancer Med; 2020 Feb; 9(3):1230-1241. PubMed ID: 31856390
[TBL] [Abstract][Full Text] [Related]
15. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients.
Li H; Liu J; Chen J; Wang H; Yang L; Chen F; Fan S; Wang J; Shao B; Yin D; Zeng M; Li M; Li J; Su F; Liu Q; Yao H; Su S; Song E
Nat Commun; 2018 Apr; 9(1):1614. PubMed ID: 29691399
[TBL] [Abstract][Full Text] [Related]
16. Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer.
Papadaki C; Stratigos M; Markakis G; Spiliotaki M; Mastrostamatis G; Nikolaou C; Mavroudis D; Agelaki S
Breast Cancer Res; 2018 Jul; 20(1):72. PubMed ID: 29996899
[TBL] [Abstract][Full Text] [Related]
17. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance).
Chumsri S; Sperinde J; Liu H; Gligorov J; Spano JP; Antoine M; Moreno Aspitia A; Tan W; Winslow J; Petropoulos CJ; Chenna A; Bates M; Weidler JM; Huang W; Dueck A; Perez EA
Clin Cancer Res; 2018 Jul; 24(13):3053-3058. PubMed ID: 29530935
[No Abstract] [Full Text] [Related]
18. Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer.
Huang X; Yuan T; Liang M; Du M; Xia S; Dittmar R; Wang D; See W; Costello BA; Quevedo F; Tan W; Nandy D; Bevan GH; Longenbach S; Sun Z; Lu Y; Wang T; Thibodeau SN; Boardman L; Kohli M; Wang L
Eur Urol; 2015 Jan; 67(1):33-41. PubMed ID: 25129854
[TBL] [Abstract][Full Text] [Related]
19. Plasma microRNAs Predict Chemoresistance in Patients With Metastatic Breast Cancer.
Shao B; Wang X; Zhang L; Li D; Liu X; Song G; Cao H; Zhu J; Li H
Technol Cancer Res Treat; 2019 Jan; 18():1533033819828709. PubMed ID: 30786836
[TBL] [Abstract][Full Text] [Related]
20. Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer.
Gong C; Tan W; Chen K; You N; Zhu S; Liang G; Xie X; Li Q; Zeng Y; Ouyang N; Li Z; Zeng M; Zhuang S; Lau WY; Liu Q; Yin D; Wang X; Su F; Song E
EBioMedicine; 2016 Sep; 11():199-209. PubMed ID: 27566954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
